Viki Bockstal
Overview
Explore the profile of Viki Bockstal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valayer S, Alexandre M, Prague M, Beavogui A, Doumbia S, Kieh M, et al.
Emerg Microbes Infect
. 2024 Nov;
14(1).
PMID: 39559990
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data...
2.
Lacabaratz C, Durand M, Wiedemann A, Foucat E, Surenaud M, Krief C, et al.
J Infect Dis
. 2024 Jul;
231(1):230-240.
PMID: 39012798
Background: The EBL2001 phase 2 trial tested the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to European Union market authorization in 2020. Complementary analyses...
3.
Ake J, Paolino K, Hutter J, Cicatelli S, Eller L, Eller M, et al.
Vaccines (Basel)
. 2024 May;
12(5).
PMID: 38793748
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind,...
4.
Barry H, Lhomme E, Surenaud M, Nouctara M, Robinson C, Bockstal V, et al.
PLoS Negl Trop Dis
. 2024 Apr;
18(4):e0011500.
PMID: 38603720
Background: The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the...
5.
Alexandre M, Prague M, McLean C, Bockstal V, Douoguih M, Thiebaut R
NPJ Vaccines
. 2023 Nov;
8(1):174.
PMID: 37940656
The persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody...
6.
Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop J, et al.
NPJ Vaccines
. 2022 Nov;
7(1):156.
PMID: 36450746
Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for...
7.
Bockstal V, Shukarev G, McLean C, Goldstein N, Bart S, Gaddah A, et al.
PLoS One
. 2022 Oct;
17(10):e0274906.
PMID: 36197845
Background: Though clinically similar, Ebola virus disease and Marburg virus disease are caused by different viruses. Of the 30 documented outbreaks of these diseases in sub-Saharan Africa, eight were major...
8.
Wagstaffe H, Anzala O, Kibuuka H, Anywaine Z, Sirima S, Thiebaut R, et al.
Vaccines (Basel)
. 2022 Jun;
10(6).
PMID: 35746491
Natural killer cells play an important role in the control of viral infections both by regulating acquired immune responses and as potent innate or antibody-mediated cytotoxic effector cells. NK cells...
9.
Anywaine Z, Barry H, Anzala O, Mutua G, Sirima S, Eholie S, et al.
PLoS Med
. 2022 Jan;
19(1):e1003865.
PMID: 35015777
Background: Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess...
10.
Bockstal V, Gaddah A, Goldstein N, Shukarev G, Bart S, Luhn K, et al.
NPJ Vaccines
. 2021 Dec;
6(1):157.
PMID: 34930928
Two phase 3 clinical studies were conducted in the USA to bridge across different Ad26.ZEBOV manufacturing processes and sites, and to evaluate the immunogenicity of different dose levels of Ad26.ZEBOV...